Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study

•Baseline characteristics of MS patients differed by region in Teri-PRO.•Teriflunomide improved treatment satisfaction regardless of baseline differences.•More patients in the rest of world reported hair thinning than in the United States.•Teriflunomide was effective in both black and white patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis and related disorders 2019-06, Vol.31, p.157-164
Hauptverfasser:	Coyle, Patricia K., Khatri, Bhupendra, Edwards, Keith R., Meca-Lallana, José E., Cavalier, Steve, Rufi, Pascal, Benamor, Myriam, Poole, Elizabeth M., Robinson, Miqun, Gold, Ralf
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Crotonates - therapeutic use Disability outcomes Female Geographical regions Humans Immunologic Factors - therapeutic use Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - drug therapy Patient Reported Outcome Measures Patient-reported outcomes Prospective Studies Teriflunomide Toluidines - therapeutic use Treatment Outcome Treatment satisfaction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!